"Evotec AG and Roche announced today that they have entered into an
agreement for Phase II clinical development of EVT 101 in patients
with treatment-resistant depression. The potential value of this
transaction exceeds USD 300 million."
Powered by LSoft's LISTSERV(R) list management software